Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil - Seite 2

Jack Weinstein
Chief Financial Officer and Treasurer
[e-mail]  
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
[phone]
[e-mail]
 

 

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether NeuroRx's recently submitted application to the FDA seeking EUA for aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial will be approved, (ii) whether RELIEF THERAPEUTICS Holding SA will be successful in its lawsuit against NRx's subsidiary, NeuroRx, and NeuroRx's CEO, Jonathan Javitt, and in defending NeuroRx’s recently filed lawsuit against Relief, (iii) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19 or any other disease, and (iv) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX and with the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

---

End of ad hoc announcement

---

Language:	English
Company:	Relief Therapeutics Holding SA
	Avenue de Secheron 15
	1202 Geneva
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	https://relieftherapeutics.com
ISIN:	CH0100191136
Valor:	10019113
Listed:	SIX Swiss Exchange
EQS News ID:	1373487